Understanding multi‐stakeholder needs, preferences and expectations to define effective practices and processes of patient engagement in medicine development: A mixed‐methods study
Open Access
- 17 February 2021
- journal article
- research article
- Published by Wiley in Health Expectations
- Vol. 24 (2) , 601-616
Abstract
Background: The holistic evolution of patient engagement in medicines development requires a more detailed understanding of the needs of all involved stakeholders, and one that better accounts for the specific needs of some potentially vulnerable patient populations and key stages in medicines development.Objective: The purpose of this convergent mixed‐methods study was to better understand the needs of different stakeholders concerning patient engagement at three key stages in medicines development: research priority setting, clinical trial design and early dialogues with Health Technology Assessment bodies and regulators.Design: This study brought together findings from three sources: i) an online questionnaire, ii) face‐to‐face consultations with two potentially vulnerable patient populations, a workshop with Health Technology Assessment bodies, and iii) three‐step modified Delphi methodology.Results: Overall stakeholders still need additional varied support mechanisms to undertake, sustain or measure value of patient engagement. Health Technology Assessment bodies need better rationale for patient engagement in early dialogue and tools to support its implementation. Improved awareness and understanding of the need and value that involving patients, who are often considered as potentially vulnerable, can bring is needed, as is better accommodation of their specific needs. Similarly, weighted Delphi categories were as follows: aims and objectives, and sustainability. Several additional themes were common across the three key stages in medicines development.Conclusion: This broad‐reaching study provides the blocks needed to build a framework for patient engagement in medicines development.Patient or Public Contribution: Patients were involved in review and interpretation of data.Keywords
Funding Information
- Innovative Medicines Initiative (Grant agreement number 777450)
This publication has 27 references indexed in Scilit:
- Using the modified Delphi method to establish clinical consensus for the diagnosis and treatment of patients with rotator cuff pathologyBMC Medical Research Methodology, 2016
- What do pharmaceutical industry professionals in Europe believe about involving patients and the public in research and development of medicines? A qualitative interview studyBMJ Open, 2016
- Partnering With Patients in the Development and Lifecycle of Medicines: A Call for ActionTherapeutic Innovation & Regulatory Science, 2015
- From tokenism to meaningful engagement: best practices in patient involvement in an EU projectResearch Involvement and Engagement, 2015
- What the public knows and wants to know about medicines research and development: a survey of the general public in six European countriesBMJ Open, 2015
- Evidence-Based Approach to Fiber Supplements and Clinically Meaningful Health Benefits, Part 1Nutrition Today, 2015
- Patient-Focused Drug DevelopmentMedical Care, 2015
- Patient involvement in research programming and implementationHealth Expectations, 2014
- A comparison of formal consensus methods used for developing clinical guidelinesJournal of Health Services Research & Policy, 2006
- A Ladder Of Citizen ParticipationJournal of the American Institute of Planners, 1969